Tobias L Freitag, Riku Fagerlund, Nihay Laham Karam, Veli-Matti Leppänen, Hasan Ugurlu, Ravi Kant, Petri Mäkinen, Ahmed Tawfek, Sawan Kumar, Tomas Strandin, Katarzyna Leskinen, Jussi Hepojoki, Tapio Kesti, Lauri Kareinen, Suvi Kuivanen, Emma Koivulehto, Aino Sormunen, Svetlana Laidinen, Ayman Khattab, Päivi Saavalainen, Seppo Meri, Anja Kipar, Tarja Sironen, Olli Vapalahti, Kari Alitalo, Seppo Ylä-Herttuala, Kalle Saksela
The ongoing SARS-CoV-2 pandemic is controlled but not halted by public health measures and mass vaccination strategies which have exclusively relied on intramuscular vaccines. Intranasal vaccines can prime or recruit to the respiratory epithelium mucosal immune cells capable of preventing infection. Here we report a comprehensive series of studies on this concept using various mouse models, including HLA class II-humanized transgenic strains. We found that a single intranasal (i.n.) dose of serotype-5 adenoviral vectors expressing either the receptor binding domain (Ad5-RBD) or the complete ectodomain (Ad5-S) of the SARS-CoV-2 spike protein was effective in inducing i) serum and bronchoalveolar lavage (BAL) anti-spike IgA and IgG, ii) robust SARS-CoV-2-neutralizing activity in the serum and BAL, iii) rigorous spike-directed T helper 1 cell/cytotoxic T cell immunity, and iv) protection of mice from a challenge with the SARS-CoV-2 beta variant...
April 14, 2023: Vaccine